Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderatedyslipidemia: Role for nitric oxide and interleukin-6

American Journal of Cardiovascular Disease

Volumn 4, Issue 3, 2014, Pages 114-122

  Cavieres, Vanessa ^a   Valdes, Karla ^a   Moreno, Brayan ^a   Moore Carrasco, Rodrigo ^b   Gonzalez, Daniel R ^a,b  

^a Departamento de Ciencias Basicas Biomedicas   (Chile)

^b UNIVERSIDAD DE TALCA   (Chile)

Author keywords

apoE; Atherosclerosis; Endothelial dysfunction; eNOS; Nitric oxide

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PHENYLEPHRINE; POTASSIUM CHLORIDE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL TISSUE; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VASODILATATION; WESTERN BLOTTING;

EID: 84907976596     PISSN: None     EISSN: 2160200X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
2. Libby P, Ridker PM and Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
3. Bonetti PO, Lerman LO and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
4. Figueroa XF, Gonzalez DR, Puebla M, Acevedo JP, Rojas-Libano D, Duran WN and Boric MP. Coordinated endothelial nitric oxide synthase activation by translocation and phosphorylation determines flow-induced nitric oxide production in resistance vessels. J Vasc Res 2013; 50: 498-511.
5. Duran WN, Breslin JW and Sanchez FA. The NO cascade, eNOS location, and microvascular permeability. Cardiovasc Res 2010; 87: 254-261.
6. Goldschmidt-Clermont PJ, Dong C, Seo DM and Velazquez OC. Atherosclerosis, inflammation, genetics, and stem cells: 2012 update. Curr Atheroscler Rep 2012; 14: 201-210.
7. Tziomalos K, Athyros VG, Karagiannis A and Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010; 20: 140-146.
8. Napoli C, de NF, Williams-Ignarro S, Pignalosa O, Sica V and Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide 2006; 15: 265-279.
9. Kofler S, Nickel T and Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) 2005; 108: 205-213.
10. Sprague AH and Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539-552.
11. Lerman A and Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 111: 363-368.
12. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM and Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
13. Zhang SH, Reddick RL, Piedrahita JA and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-471.
14. D’Uscio LV, Barton M, Shaw S and Luscher TF. Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc Res 2002; 53: 487-495.
15. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T and Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-1288.
16. D’Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC and Katusic ZS. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 1017-1022.
17. Amar J, Fauvel J, Drouet L, Ruidavets JB, Perret B, Chamontin B, Boccalon H and Ferrieres J. Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens 2006; 24: 1083-1088.
18. Lindmark E, Diderholm E, Wallentin L and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
19. Saura M, Zaragoza C, Bao C, Herranz B, Rodriguez-Puyol M and Lowenstein CJ. Stat3 mediates interleukin-6 [correction of interelukin-6] inhibition of human endothelial nitric-oxide synthase expression. J Biol Chem 2006; 281: 30057-30062.
20. Hung MJ, Cherng WJ, Hung MY, Wu HT and Pang JH. Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J Hypertens 2010; 28: 940-951.
21. Fransen P, Van AT, Guns PJ, Van Hove CE, De Keulenaer GW, Herman AG and Bult H. Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflugers Arch 2008; 455: 811-818.
22. Van AT, Fransen P, Guns PJ, Herman AG and Bult H. Altered Ca2+ handling of smooth muscle cells in aorta of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Cell Calcium 2007; 41: 295-302.